NasdaqGM:ADMABiotechs
ADMA Biologics (ADMA) Stock May Be Undervalued After Fraud Lawsuit Filing
ADMA Biologics stock has delivered a very large 5 year gain, yet the broader valuation checks currently lean cheap, setting up a clear tension between past returns and what the market is asking investors to pay today.
Over the past 5 years, ADMA Biologics has returned almost 7x, which puts extra focus on whether the current price still reflects a reasonable entry point after such a strong run.
Potential margin expansion and progress on its hyperimmune globulin candidate for pneumococcal...